Elan's second-quarter revenues up 14% on strong Tysabri sales, net loss narrows
This article was originally published in Scrip
Executive Summary
Elan's second-quarter net revenues rose by 14% to $280.9 million following strong Tysabri (natalizumab) sales, and its net loss narrowed by 5% to $68.2 million. This amounted to a net loss of $0.14 per share compared with $0.15 per share in the same period last year.